- Home
- BEAM vs TDOC Comparison
BEAM vs TDOC Comparison
Compare BEAM & TDOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- TDOC
- Stock Information
- Founded
- BEAM 2017
- TDOC 2002
- Country
- BEAM United States
- TDOC United States
- Employees
- BEAM N/A
- TDOC N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- TDOC Medical/Nursing Services
- Sector
- BEAM Health Care
- TDOC Health Care
- Exchange
- BEAM Nasdaq
- TDOC Nasdaq
- Market Cap
- BEAM 1.7B
- TDOC 1.4B
- IPO Year
- BEAM 2020
- TDOC 2015
- Fundamental
- Price
- BEAM $21.28
- TDOC $7.67
- Analyst Decision
- BEAM Strong Buy
- TDOC Buy
- Analyst Count
- BEAM 10
- TDOC 17
- Target Price
- BEAM $48.56
- TDOC $9.80
- AVG Volume (30 Days)
- BEAM 2.9M
- TDOC 4.3M
- Earning Date
- BEAM 11-04-2025
- TDOC 10-29-2025
- Dividend Yield
- BEAM N/A
- TDOC N/A
- EPS Growth
- BEAM N/A
- TDOC N/A
- EPS
- BEAM N/A
- TDOC N/A
- Revenue
- BEAM $60,272,000.00
- TDOC $2,542,268,000.00
- Revenue This Year
- BEAM N/A
- TDOC $0.09
- Revenue Next Year
- BEAM $17.95
- TDOC $1.09
- P/E Ratio
- BEAM N/A
- TDOC N/A
- Revenue Growth
- BEAM N/A
- TDOC N/A
- 52 Week Low
- BEAM $13.53
- TDOC $6.35
- 52 Week High
- BEAM $35.25
- TDOC $15.21
- Technical
- Relative Strength Index (RSI)
- BEAM 62.79
- TDOC 51.07
- Support Level
- BEAM $19.57
- TDOC $7.47
- Resistance Level
- BEAM $21.59
- TDOC $7.85
- Average True Range (ATR)
- BEAM 1.24
- TDOC 0.23
- MACD
- BEAM 0.48
- TDOC 0.00
- Stochastic Oscillator
- BEAM 94.43
- TDOC 42.50
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About TDOC Teladoc Health Inc.
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with improved convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.